FDA Inspection 1196520 — ImpactLife

ImpactLife — FEI 3011078001

The FDA completed an inspection of ImpactLife on January 24, 2023 in Springfield, IL. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
January 24, 2023
Fiscal Year
2023
Product Type
Biologics
Project Area
Blood and Blood Products
Location
Springfield, IL (United States)